Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | PGK2 | P07205 | 1/20 | 0.43 |
| ▸ | TKT | P29401 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5916304 | 0.83 | LMNA (0.50) | LMNATDP1TKTKDM4ENFKB1 | |
| Phosphoric Acid SCHEMBL851329 | 0.83 | LMNA (0.53) | LMNATDP1TKT | |
| Phosphoric Acid SCHEMBL1533803 | 0.83 | LMNA (0.53) | LMNATDP1TKT | |
| SCHEMBL13176800 | 0.82 | PGK1 (0.46) | LMNATDP1PGK1PGK2 | |
| SCHEMBL3371360 | 0.79 | LMNA (0.61) | LMNATDP1TKT | |
| Pyrophosphoric Acid SCHEMBL851327 | 0.78 | LMNA (0.51) | LMNATDP1TKT | |
| SCHEMBL12346332 | 0.77 | LMNA (0.63) | LMNATKTKDM4E | |
| SCHEMBL479344 | 0.76 | LMNA (0.61) | LMNATKTKDM4E | |
| SCHEMBL851328 | 0.74 | LMNA (0.57) | LMNATDP1TKT | |
| Hydrochloric Acid SCHEMBL6520994 | 0.74 | LMNA (0.59) | LMNATKTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | PYRO PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
| EP-2463654-B1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | UNIV CALIFORNIA (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20150353941-A1 | Genetically Modified Biological Cells | O'KEEFE THERESA (US) | 2015-12-10 | — | — | US | disclosed |
| US-8311790-B2 | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | UNIVERSITY OF DELAWARE (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2463654-A1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8170852-B2 | Data structures and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100280803-A1 | Compositions and Methods for Modeling Saccharomyces cerevisiae Metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-11-04 | — | — | US | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-7751981-B2 | Articles of manufacture and methods for modeling Saccharomyces cerevisiae metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006040-A1 | Method for the identification and treatment of pathogenic microorganism infections by inhibiting one or more enzymes in an essential metabolic pathway and compounds and pharmaceutical compositions useful therefor | CYP51A1, ME1, BPGM | LMNA 3872/4885TDP1 3936/4885PGK1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.